Screening of significantly hypermethylated genes in breast cancer using microarray-based methylated-CpG island recovery assay and identification of their expression levels.

To screen candidate methylation markers for early detection of breast cancer and to explore the relationship between methylation and gene expression, we performed methylated-CpG island recovery assay (MIRA) combined with CpG island array on 61982 CpG sites across 4162 genes in 10 cancerous and 10 non-cancerous breast tissues. Direct bisulfite sequencing and combined bisulfite restriction analysis (COBRA) were carried out in independent cancerous and non-cancerous samples. Gene expression was analyzed by microarrays and validated using RT-PCR. We detected 70 significantly hypermethylated genes in breast cancer tissues, including many novel hypermethylated genes such as ITGA4, NFIX, OTX2 and FGF12. Direct bisulfite sequencing showed widespread methylation occurring in intragenic regions of the WT1, PAX6 and ITGA4 genes and in the promoter region of the OTX2 gene in breast cancer tissues. COBRA assay confirmed that the WT1, OTX2 and PAX6 genes were hypermethylated in breast cancer tissues. Clustering analysis of the gene expression of 70 significantly hypermethylated genes revealed that most hypermethylated genes in breast cancer were not expressed in breast tissues. RT-PCR assay confirmed that WT1 and PITX2 were only weakly expressed in the breast cancer tissues and were not expressed in most non-cancerous breast tissues. OTX2 and PAX6 were not expressed in either breast cancer or non-cancerous tissues. In conclusion, these results will expand our knowledge of hypermethylated genes and methylation sites for early detection of breast cancer and deepen our understanding of the relationship between methylation and gene expression. The MIRA approach can screen candidate methylated genes for further clinical validation more effectively than gene expression microarray-based strategy.

[1]  A. Riggs,et al.  Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay , 2007, Proceedings of the National Academy of Sciences.

[2]  W. Chong,et al.  Identification of submicroscopic chromosomal aberrations in fetuses with increased nuchal translucency and apparently normal karyotype , 2011, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[3]  Yun Yen,et al.  Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer , 2009, Breast Cancer Research.

[4]  Jennifer D. Brooks,et al.  Promoter methylation and the detection of breast cancer , 2009, Cancer Causes & Control.

[5]  Manfred Schmitt,et al.  DNA methylation as a biomarker in breast cancer. , 2009, Future oncology.

[6]  C. Roberts,et al.  Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[7]  G. Tsujimoto,et al.  Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput sequencing , 2010, BMC Genomics.

[8]  M. Monden,et al.  Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer , 2007, British Journal of Cancer.

[9]  T. Rauch,et al.  The MIRA method for DNA methylation analysis. , 2009, Methods in molecular biology.

[10]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[11]  P. Laird,et al.  COBRA: a sensitive and quantitative DNA methylation assay. , 1997, Nucleic acids research.

[12]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[13]  L. Myeroff,et al.  Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. , 2005, Journal of the National Cancer Institute.

[14]  J. Foekens,et al.  Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Rauch,et al.  CpG island hypermethylation in human astrocytomas. , 2010, Cancer research.

[16]  Colm E. Nestor,et al.  Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer , 2011, Proceedings of the National Academy of Sciences.

[17]  C. Atalay.  Epigenetics in breast cancer. , 2013, Experimental oncology.

[18]  C. B. Patel,et al.  Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. , 2001, Cancer research.

[19]  D. Lubahn,et al.  Hypermethylation of the Wilms' tumor suppressor gene CpG island in human breast carcinomas , 1999, Breast Cancer Research and Treatment.

[20]  E. Feierstein,et al.  DNA Methylation of the First Exon Is Tightly Linked to Transcriptional Silencing , 2011, PloS one.

[21]  F. López-Ríos,et al.  IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer , 2010, Oncogene.

[22]  A. Zinn,et al.  Cryptic Chromosomal Abnormalities Identified in Children With Congenital Heart Disease , 2008, Pediatric Research.

[23]  J. Foekens,et al.  DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and , 2007, European journal of cancer.